Drug Profile
Ivabradine extended release - Abbott Healthcare
Alternative Names: Ivabradine prolonged releaseLatest Information Update: 06 Jan 2023
Price :
$50
*
At a glance
- Originator Abbott Healthcare
- Class Benzazepines; Bradycardic agents; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Hyperpolarisation activated cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Angina pectoris; Chronic heart failure
Most Recent Events
- 06 Jan 2023 No development reported - Phase-III for Chronic heart failure in India (PO)
- 28 Nov 2019 No recent reports of development identified for phase-I development in Angina-pectoris(In volunteers) in India (PO, Controlled release)
- 21 May 2018 Abbott Healthcare plans a phase III trial in stable Chronic heart failure (in patients with systolic dysfunction) in India (PO, Controlled release) (CTRI2018-04-013464)